Trials / Completed
CompletedNCT01110746
To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy
A Double-blind Study of the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Biodel · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin during SC Insulin Pump Therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Viaject 7 | 100IU/mL administered subcutaneously |
| DRUG | LISPRO | 100IU/mL administered subcutaneously |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2010-06-01
- Completion
- 2010-06-01
- First posted
- 2010-04-27
- Last updated
- 2015-08-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01110746. Inclusion in this directory is not an endorsement.